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Abstract: 
 
Alzheimer’s disease is a progressive neurodegenerative disease that affects million of Americans 
every year for which no cure exists. Alzheimer’s disease (AD) pathology involves the 
accumulation of tau protein isoforms and amyloid-β (Aβ) in brain tissue leading to degradation 
of cortical brain regions such as the hippocampus. It is hypothesized that an imbalance between 
the production and clearance of tau and Aβ leads to plaque accumulation and neuronal cell death. 
Clearance is achieved via glymphatic circulation which is facilitated by aquaporin 4 (Aqp4) 
water channel proteins, and it is believed that diminished ISF bulk flow leads to accumulation of 
tau and Aβ. Here, a new mouse model was generated utilizing strategy crosses between an 
existing AD mouse model (3xTg-AD) and a Aqp4 KO mouse model, predicting that this new 
model would show an accelerated AD phenotype characterized by increased tau deposits in 
mouse cortical regions. In parallel, gene therapy using an AAV9-GFAP-Aqp4 construct was 
used to evaluate the therapeutic efficacy of Aqp4 expression on tau levels. The double transgenic 
mouse (3xTg-AD;Aqp4 KO) was genotyped and characterized via western blot. We observed 
that the 3xTg-AD;Aqp4 KO mice exhibit significantly more tau protein levels at a younger age 
compared with older 3xTg-AD mice. We also observed greater total tau levels in the 
hippocampus compared to whole brain tissue. Gene therapy on 3xTg-AD;Aqp4 KO mice treated 
with an AAV9-GFAP-Aqp4 construct resulted in a reduction of tau specifically in the 
hippocampus. Further characterization using immunohistochemistry, staining for different 
proteins and metabolites, and comparison of charactersitic neurodegenerative pathology with 
other AD mouse models is necessary to fully understand the pathology of this new (3xTg-
AD;Aqp4 KO) mouse model. These findings provide evidence that clearance of interstitial 
fluid/metabolic waste including tau protein is impacted by the aquaporin 4 water channel, and 
that Aqp4 may serve as a thereputic candidate for future trials investigating treatments for 
neurodegenerative diseases.  
 
Introduction: 
 
Alzheimer disease (AD) affects millions of Americans every year and involves the 
accumulation of tau and amyloid-β deposits in brain tissue leading to degradation of neural 
function (1). Tau microtubule associated protein (tau) can be posttranslationally and 
conformationally modified to produce both soluble and insoluble forms of tau intraneuronally. 
The insoluble forms of tau are hyperphosphorylated and produce paired helical neurofibrillary 
tangles, a hallmark of Alzheimer’s disease (2). Other, more soluble, forms of tau are also 
hypothesized to contribute to Alzheimer’s pathology and the question of which pathological 
forms of tau are responsible for Alzheimer’s disease pathology is still not known(3).  Amyloid-β 
deposits are derived from cleavage of a larger protein, the Amyloid Precursor Protein (APP), by 
the enzymes β-and γ-secretase and further processes clear these proteins from the cell(4,5). It is 
hypothesized that an imbalance in the production and clearance of tau and Amyloid- β leads to 
plaque deposition and results in damage to synapses and death of neurons (6,7). 
Existing treatments of AD only target the symptoms of patient and not the underlying 
mechanisms leading to AD pathology. Currently most licensed AD treatments utilize various 
cholinesterase inhibitors and NMDA receptor antagonists to manage patient symptoms. There 
have been trials that target production of Aβ using active immunization of individuals with Aβ 
deposits and passive immunization with Aβ antibodies (8). However, these trials led to no 
conclusions in phase I and were terminated in phase II due to development of autoimmune 
meningoencepalitis (8). An alternative treatment option of Alzheimer’s disease involves 
inhibition/regulation of three proteases that are involved in the processing of amyloid precursor 
protein—α-secretase, β-secretase and γ-secretase (9,10,11). Therapies targeting tau pathology 
have increased dramatically in recent years as tau has been hypothesized to link more with the 
cognitive deficits associated with AD (12). Tau therapies have mostly focused on 
immunotherapy and resulted in some promising animal studies. Therapies targeting both tau and 
Aβ have proven inconclusive and have not produced any meaningful novel therapeutic options, 
leaving there no current treatment for the disease. 
         Here, a new promising therapeutic approach targets the clearance of tau from the brain 
that would otherwise aggregate and possibly lead to Alzheimer’s disease. The brain lacks 
lymphatic circulation, and uses paravascular pathways, which engage in the exchange of water 
and soluble proteins between cerebrospinal (CSF) and interstitial fluids (ISF) (13). ISF bulk flow 
facilitated by the astrocytic aquaporin 4 (Aqp4), otherwise known as the glymphatic system, has 
been hypothesized as a possible clearance mechanism for soluble proteins, which accumulate in 
the case of Alzheimer’s disease and other neurodegenerative diseases(13,14). 
         This study seeks to better understand the role of Aqp4 in the clearance of tau using both 
an AD mouse model and a novel transgenic AD mouse model. Studies from our lab provide 
evidence that Aqp4 knockout mice (KO) show reduced interstitial clearance of fluorescent 
tracers from the brain (14). With this in mind we crossed an Aqp4 KO mouse with an existing 
AD mouse model termed 3xTg-AD. The 3xTg-AD mouse model is transgenic for 3 mutations 
that lead to AD pathology. The three independent mutations include an APP K670N/M671 , Swedish 
double mutation of the human amyloid precursor protein (APP) gene that overexpresses APP 
(15). This overexpression of APP leads to an increase in Aβ deposits. The trigenic mouse model 
also has MAPT P301L (frontotemporal dementia mutation called tauP301), which increases tau 
formation. Tau formation like the accumulation of Aβ deposits leads to neurodegeneration and 
dementia (15). Also, this mouse model has a Psen1 mutation or a mutation in a subunit of 
gamma- (γ-) secretase called presenilin 1, which leads to dysfunction in the processing of APP 
and ultimately, the accumulation of Amyloid- β (16). This new double transgenic mouse model 
termed (3xTg-AD;Aqp4 KO) will allow further examination of the role Aqp4 plays in the 
clearance of tau and Aβ deposits. 
         The second goal of this study was to evaluate the therapeutic efficacy of a novel gene 
therapy approach using adeno associated viral vectors. Restoration of Aqp4 function in our new 
(3XTG;AQP4 KO) model was accomplished using astrocyte-specific AAV vectors. These AAV 
vectors were injected intravenously which was hypothesized to result in greater ISF bulk flow 
facilitated by restoration of Aqp4 function in the astrocytes of the brain leading to greater 
glymphatic circulation. This therapy is presumed to enhance tau and Aβ clearance from the brain 
and possibly lead to novel gene therapy trials for Alzheimer’s disease and other 
neurodegenerative diseases.  
 
Methods: 
Animal experiments.  
 
The Aqp4 KO mouse model was orginally provided by Alan Verkman (UCSF, San 
Francisco, California, USA). 3xTg-AD and C57/Bl6 mice were ordered from The Jackson 
Laboratory for Genomic Medicine( 10 Discovery Dr, Farmington, CT 06032). All animal 
experiments reported in this study were conducted on 3xTg-Ad, Aqp4 KO or C57/Bl6 mice bred 
and maintained in accordance to NIH guidelines, as approved by the The University of North 
Carolina at Chapel Hill Institutional Animal Care and Use Committee protocol 15-109. 
 
 
 
Development of (3xTg-AD;Aqp4 KO) mouse model 
 
Development of a 3xTg-AD;Aqp4 KO mouse model involved first crossing Aqp4 KO 
mice with 3xTg-AD mice to produce a heterozygous (3xTg-AD-/+;Aqp4-/+) F1 generation. These 
F1 generation mice were then crossed again with 3XTG-AD mice to produce (3xTg-AD;Aqp4-/+) 
mice. Another cross was then utilized using F1 mice (3xTg-AD-/+;Aqp4 KO) and (Aqp4 KO) 
mice to produce mice with the genotype  (3xTg -/+;Aqp4 KO). Mice with the genotype (3xTg-
AD;Aqp4-/+) were then crossed with mice of the genotype (3xTg -/+; Aqp4 KO) to generate our 
study animal with the genotype (3xTg-AD;Aqp4 KO).  
 
Genotyping 
Mice were genotyped in each generation using specifically designed primers from The 
Jackson Labroatory. Tissue collection for DNA extraction was accomplished via ear clippings or 
tail clippings. Tissues were lysed using proteinase K, and DNA was isolated using a DNeasy 
Blood & Tissue kit from Qiagen (19300 Germantown Road Germantown, MD 20874). A KAPA 
biosystems mouse genotyping kit (200 Ballardvale St #250, Wilmington, MA 01887) was used to 
produce our PCR ready products. For Aqp4 genotyping, a PCR reaction was set up using 3 
distinct primers designed by The Jackson Labroatory. The PCR reaction used 5 µL of KAPA2G 
Fast Genotyping Mix, 1.5µL of each primer (20 micro-mole concentration) (3 total), and .5µL 
ddH2O for each reaction. Primer information and thermocycler settings are outlined below. All 
primers were ordered through IDT technologies, primers were spun down prior to resuspension 
to prevent loss of sample. Primers were diluted to a final concentration of 100 mM and used as a 
stock concentration, which was then diluted for the working solution for each experiment.  
 A 1% agarose gel with 0.2-0.5 µg/mL of ethidium bromide was used and gel electrophoresis 
was ran at 120 V for approximately 25 minutes and analyzed under UV. A 1 kb ladder was used 
as reference. A water only control and positive control was also used when analyzing gels/PCR 
products.  
  
 
 
 
 
The method to test for the 3xTg trigenic genotype was not able to determine homozygous 
from heterozygous, simply 3xTg positive or negative by probing for the Psen1tm1Mpm allele which 
has a 3 nucleotide mutation in 3xTg positive mice. A PCR reaction was set up using 4 distinct 
primers. Each reaction used 5µL of KAPA2G Fast Genotyping Mix, 1 µL of each primer (4 
total), and 1 µL ddH2O for each reaction. Primer information and thermocycler settings are 
outlined below. A 3% agarose gel with 0.2-0.5 µg/mL of ethidium bromide was used instead of a 
1% gel used in the previous protocol in order to attain better separation of bands. Gel 
electrophoresis was ran at 120 V for approximately 25 minutes and analyzed under UV. A 1 kb 
ladder was used as reference. A water only control and positive control was also used when 
analyzing gels/PCR products.  
 Mouse Sacrificing 
Mice were sacrificed via rapid anesthetization utilizing 2.5% Avertin (tribromoethanol). 
After complete anesthetization brains were harvested after cardiac perfusions with PBS 
(phosphate buffered saline) followed by 4% paraformaldehyde (PFA) perfusion. For brain tissue 
needed to perform western blot analysis, brains were not profused with PFA, but dissected out 
and bisected down the corpus callosum (sagittal plane dissection). Half the brain tissue was 
preserved at -80 °C in Passive lysis buffer (PLB) from Promega and a HALT TM protease 
inhibitor cocktail from ThermoFischer scientific (2525 Meridian Pkwy #400, Durham, NC 
27713). The remaining brain tissue was post-fixed in a 4% PFA solution.  
 
Western blot analysis 
Western blot analysis was performed on both whole brain and hippocampal tissue 
preserved at -80 °C in a HALT TM protease inhibitor cocktail from ThermoFischer Scientific. 
After PLB and the protease inhibitor cocktail was added post-sacrificing, tissue samples were 
allowed to sit on ice for 30 minutes, then spun at 20,000 g for 4 minutes. Supernatant and tissue 
pellets was preserved at -80 °C. Equal amounts of tissue were used for a BSA assay to measure 
total protein concentration in different mice genotypes and comparing whole brain vs. 
hippocampal tissue. A Pierce™ Coomassie Plus (Bradford) Assay Kit was used and absorbance 
was measured at 595 nm. A standard curved was constructed using pre-formulated BSA 
standards and used to calculate total protein concentrations for every brain sample analyzed. 
Total protein concentrations were used to calculate the necessary sample volume to achieve 20 
µg of protein per well. 1X LDS, 1X DTT and ddH2O was used to prepare the western-blot ready 
samples to be loaded onto the gel. Gel electrophoresis was performed at 180V for 60 minutes 
using a NuPAGETM 4-12% Bis-Tris Gel. Transfer using  nitrocellulose paper was performed at 
30V for 60 minutes, followed by overnight blocking using a 5% milk blocking solution at 4 °C. 
Incubation with a TAU monoclonal antibody from ThermoFisher (#AHB0042) was performed 
overnight at 4 °C followed by a 1 hour secondary antibody incubation.  ThermoScientific 
SuperSignal West Femto Maximum Sensitivity Substrate(#34095) was used for 
chemiluminescent analysis in a Amersham 600 series CCD-based imager from GE Healthcare 
Life Sciences.  
 
Virus production/Therapy  
HEK293 cells were split 1:3, allowing for 5 x 15cm plates per virus prep. Cells were 
grown in DMEM with 5% FBS, 1% Pen/strep and left to sit overnight in a 37°C CO2 incubator. 
Cells were checked for ≈ 70% confluence before transfection. Per 5 plates: 60ug PXX680, 50ug 
pHelper (AAV9 REP/CAP plasmid), and 30ug of our transgene ITR-GFAP-Aqp4-ITR plasmid 
were used (Luciferase reporter gene also used in separate prep). Plasmids were added to 2.5 ml 
of serum free DMEM then 420 uL PEI max was added. The solution was pulsed 5-10 times and 
allowed to sit at room temperature for 5 minutes. The solution was then added drop wise to 
HEK293 cells. Media was harvested either on day 4 or 5 post-transfection and then again on day 
6 or 7 post transfection. Media was then PEG precipitated 1:5 PEG:media and incubated on ice 
overnight. The PEG/media mixture was centrifuged at 2500-3000g for 30-40 minutes. Cell 
pellets were collected, re-suspended and then DNAse treated (50uL 100mM MgCl2 and 50uL 
10mg/mL DNAse). An iodixanol gradient was used using 3.5 ml of 17%, 25%, 40%, and 60% 
iodixanol then virus prep was added on top and placed in an ultracentrifuge at 30,000 rpm 
overnight. Post- centrifugation, 1.5 ml fractions were collected and qPCR was used to determine 
the fraction containing the most virus. The fractions with the most virus were then desalted and 
qPCR was used to determine virus titer. Virus was aliquoted and stored prior to injection in mice. 
Mice were sacrificed 6 weeks post-injection with one of three treatments outlined below and 
brain tissue was collected as described previously.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Results.  
 
Generation of 3xTg-AD;Aqp4 KO mice. We first performed a cross of 3xTg-AD and Aqp4 
KO mice to generate a F1 generation heterozygotes for both genotype (no gel shown). We then 
performed a cross between F1 (3xTg -/+;Aqp4 -/+) mice and 3xTg-AD mice, to generate 13 total 
offspring(Fig. 1A). Genotyping results (Fig. 1B) shows only testing for the Aqp4 genotype as all 
offspring would either be homozygous or heterozygous for the 3xTg trigenic mutations which 
would not be discerned with the genotyping protocol used. Assuming mendelian genetics, 50% 
of offspring were expected to be heterozygous for the Aqp4 gene (1 functional allele) and 50% 
wildtype Aqp4 gene (2 functional alleles). This was observed in real time with approximately 
6/13 of the offspring being heterozygous and all either being homozygous or heterozygous for 
the 3xTg trigenic mutations (Fig. 1B). We then utilized a backcross involving an F1 (3xTg -
/+;Aqp4 -/+)  mouse and an Aqp4 KO mouse (Fig. 1A) to generate 10 total offspring. Mendelian 
genetics was approximately observed with 3/10 of the offspring being our target 3xTg -/+;Aqp4 
KO genotype (Fig. 1C). Our final cross was between our  (3xTg-AD;Aqp4 -/+) mice generated 
in cross 1 (Fig. 1A) and (3xTg -/+;Aqp4 KO) mice generated in cross 2 (Fig. 1A) to generate the 
genotype of interest (3xTg-AD;Aqp4 KO).  Mendelian genetics was approximately observed 
with 5/13 of the offspring being Aqp4 knockouts and approximately all being 3xTg positive 
(Note: 4 samples did not have proper DNA extraction) (Fig. 1D). It is important to note that 
although the genotyping method used could not distinguish mice hemizygous or homozygous for 
the 3 transgenes, mice hemizygous for the 3 transgenes display the same neuropathological 
changes as homozygous mice (15). Also, crossing these mice to other genetically modified mice 
does not require returning the original three transgenes to a homozygous state (15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Strategy crosses and genotyping for generation of 3xTg-AD ;Aqp4 KO mice 
(A) Diagram depicting 4 crosses utilized. (B) Genotyping results of cross 2 “B”, note that 
all offspring were 3xTg positive. (C) Genotyping results of cross 3 “C” testing for both 
3xTg and Aqp4 genotypes. (D) Genotyping results of cross 4 “D”.  A 240 bp signal 
signifies WT and 320 bp signal signifies a mutant(KO) Aqp4. The 3xTg transgene is 377 
bp and internal positive control is 324 bp. Note: the genotyping protocol can not 
distinguish between heterozygotes and homozygous for the 3xTg triple transgenic 
allele. 
 
Younger (3xTg-AD;Aqp4 KO) mice have greater tau levels than older 3xTg-AD mice. 
3xTg-AD mice develop an age-related and progressive neuropathological phenotype including 
both Aβ plaque and tau pathology (15). Cognitive impairment is seen in both heterozygous and 
homozygous 3xTg-AD mice at 4 months of age and this is correlated with accumulation of 
intraneuronal Aβ in the hippocampus and amygdala, but tau and Aβ are not detected at this age 
(15). We performed western blot analysis of total tau protein levels in younger approximately 4 
month old (3xTg-AD;Aqp4 KO) mice compared to older approximately 9 month old 3xTg-AD 
mice to examine how impairment of the glymphatic system via knockout of the aquaporin 4 
water channel would affect tau protein levels in whole brain tissue. Tau was detected at 
approximately 55kDa and 25kDA. Total tau levels in whole brain tissue samples of ≈ 4 month 
old 3xTg-AD;Aqp4 KO were greater than total tau levels in older ≈ 9 month old 3xTg-AD mice 
(Fig. 2). 
					
Figure 2. Western blot analysis was 
performed using a tau monoclonal 
antibody (TAU-5 #AHB0042). 
Total tau levels were analyzed 
using whole brain samples from 
two ≈ 4 month old 3xTg-AD;Aqp4 
KO and two ≈ 9 month old 3xTg-
Ad mice which served as a 
intermediate-age positive control 
for progressive neuropathological 
tau and Aβ accumulation. Beta-
actin was used as a loading control. 
Tau was detected at 50kDa and 
25kD in both 3xTg-AD;Aqp4 KO 
mice and 3xTg –AD mice. NOTE: 
The Amersham 600 series imager 
obtains chemiluminescence data 
and overlays it upon the 
colorimetric data, which includes 
the stained protein ladder. Both a 
grey-scale chemiluminescene blot 
and a combined colorimetric and 
chemiluminescene grey-scale blot is 
included.  	
 
Generation of therapeutic AAV9 vector. We observed that total tau levels in whole brain 
samples of 3xTg-AD;Aqp4 KO mice were greater than tau levels in aged 3xTg-Ad mice. We 
next wanted to examine the therapeutic benefit of using an AAV9 vector to introduce an Aqp4 
transgene. AAV9 was chosen as the AAV serotype with the most therapeutic promise due to its 
ability to cross the blood-brain barrier and its high localization in the CNS. The transgene 
plasmid map includes an astrocyte specific GFAP promoter, which localizes Aqp4 cDNA 
expression to the end-feet of astrocytes (Fig. 3). This restoration of Aqp4 function presumably 
restores glymphatic transport and thus, the therapeutic benefit of an AAV9-GFAP-Aqp4 
construct on tau pathology, Aβ pathology, and behavior can be studied in our 3xTg-AD;Aqp4 
KO mouse model.  
 
 Figure 3. Production of therapeutic AAV9 vector packaging Aqp4 cDNA with an astrocyte 
specific GFAP promoter. A pAAV-GFAP-Aqp4 plasmid was designed and transfected into 
HEK293 cells with a pXX680 helper plasmid and AAV9-rep/cap plasmid. Depicted is the 
production of AAV9 capsids packaging the therapeutic GFAP-Aqp4 construct flanked by ITRs 
to be injected intravenously into our 3xTg-AD;Aqp4 KO mice. Note: Aqp4 primers used to 
genotype mice in Figure 1 are mapped onto the pAAV-GFAP-Aqp4 plasmid map. 
 
 
Gene therapy utilizing an AAV9-GFAP-Aqp4 construct resulted in a reduction of total tau 
levels in the hippocampus of 3xTg-AD;Aqp4 KO mice. Tau pathology characteristic of 
Alzheimer’s disease is mostly restricted to the hippocampus, amygdala, and cerebral cortex of 
mice (15). We examined the therapeutic affect gene therapy utilizing an adeno associated viral 
vector (AAV9) packaging Aqp4 cDNA with an astrocyte specific GFAP promoter would have 
on total tau levels in both whole brain and isolated hippocampus samples of 3xTg-AD;Aqp4 KO 
mice. In the no-injection and AAV9-Luciferase negative control treatments, 3xTg-AD;Aqp4 KO 
mice were observed to have greater total tau levels in the hippocampus compared to the whole 
brain (Fig. 4A/B). In mice injected with the therapeutic AAV9-GFAP-Aqp4 construct, total tau 
protein levels were observed to have decreased specifically in the hippocampus compared to 
whole brain samples (Fig. 4A/B).  
 		
 
 
 
 
 
 
 
 
 
 
Figure 4. Western blot analysis was performed using a tau monoclonal antibody (TAU-5 
#AHB0042). Total tau levels were analyzed using whole brain (designated “WB” in figure 4) 
and isolated hippocampus (designated “Hip” in figure 4) samples. Two total mice were used as 
no-injection negative controls (one shown), 3 total mice were injected with AAV9 packaging a 
luciferase reporter gene (two shown) which served as a secondary negative control and 4 total 
mice were injected with the therapeutic AAV9-GFAP-Aqp4 cDNA construct (2 shown). (A) Is a 
combined colorimetric and chemiluminescene grey-scale blot. (B) Represents the individual 
chemiluminescene grey-scale blot for easier analysis. (A) Tau was detected at 50kDa and 25kD 
(tau fragment). (B) Tau was detected as 50 kDa and slightly at 25 kDa in the grey-scale blot.  (C) 
Beta-actin served as a loading control (note: b-actin blot is inverted 180 degrees on figure).  
	
Discussion.		
Our study first set out to understand the role of the Aqp4 water channel, which mediates 
glymphatic CSF flux and transparenchymal solute clearance, in the clearance of tau using an 
existing 3xTg-AD mouse model and crossing it with an Aqp4 KO mouse model. We 
successfully generated a 3xTg-AD;Aqp4 KO mouse model over multiple strategic crosses and 
evaluated total tau protein levels via western blot. We found that 3xTg-AD;Aqp4 KO mice at 
approximately 4 months of age showed increased total tau protein levels compared to more aged 
≈ 9 month old 3xTg-AD mice. This provides support for the hypothesis that the Aqp4 water 
channel not only mediates clearance of tau protein which is one of the hallmarks of Alzheimer’s 
disease, but also that gene therapy utilizing the Aqp4 water channel may be therapeutic in 
decreasing total tau protein levels in brain tissue. More studies are needed which focus on 
comparing tau levels of our 3xTg-AD;Aqp4 KO mouse model at varying ages to different 
Alzheimer’s disease mouse models, Aqp4 KO mouse models, and wildtype mouse models at 
varying ages. Time constraints limited the scope of the study, however, it is feasible to 
accomplish this aim in a follow up study with mice of varying genotypes at 4,6,9 and > 12 
months of age. Future studies should also focus on examining levels of other proteins and toxic 
metabolite such as Aβ protein, α-synuclein, or even specific tau isoforms in the 3xTg-AD;Aqp4 
KO mouse model.  
We then utilized a specific adeno associated viral vector (AAV9) packaging Aqp4 cDNA 
as a therapeutic candidate for decreasing tau levels in 3xTg-AD;Aqp4 KO mice. We used 
western blot analysis of total tau protein levels post AAV9-GFAP-Aqp4 injection and found that 
tau levels decreased specifically in the hippocampal region of 3xTg-AD;Aqp4 KO mouse brains. 
The hippocampus is critical for proper memory function and therapy utilizing a similar 
AAV9/Aqp4 construct to eliminate tau and other pathological proteins may prove beneficial to 
patients with neurodegenerative diseases. This specific reduction of total tau levels in the 
hippocampus may be due to specificity of the AAV9 serotype to transduce astrocytes in the 
hippocampus. Future studies should examine if a differential decrease in tau levels is observed in 
other critical brain regions affected in neurodegenerative diseases such as the amygdala or 
cerebellum. It has been shown that aged mice as well as Aqp4 KO mice display abnormal AAV9 
accumulation (14). Thus, it is possible that 3xTg-AD;Aqp4 KO mice displayed decreased tau 
levels specifically in the hippocampus due to a combination of greater AAV9 accumulation in 
aged/Aqp4 KO mice and differential AAV9 transduction efficiency of the hippocampus.  
Although a specific decrease of tau levels in the hippocampus may be beneficial to 
patients with neurodegenerative diseases, these findings also present a challenge in possible 
future therapeutic trials. Increased Aqp4 expression via AAV gene therapy may lead to 
decreased pathological protein levels in the brain, but can also lead to decreased AAV 
accumulation in the brains of patients and thus, decreased Aqp4 expression over time. This can 
result in utilizing high AAV doses as therapeutic trials progress and presents a challenge to avoid 
dose-dependent hepatotoxicity.  
A solution to this issue is engineering synthetic AAV capsids for efficient CNS gene 
transfer that also avoids hepatic transduction. Our lab has already developed a blueprint for 
functional mapping of the AAV capsid surface footprint in order to engineer synthetic AAV 
capsids that are able to offer improved CNS gene transfer and diminish health issues involved 
with AAV gene therapy (18). Limitations of the study include the inevitable constraints involved 
with animal work such as long gestation times for mice, necessary wait period to study 4,6,9 
month old mice. Also, to get a complete picture of how the Aqp4 water channel affects 
pathology in 3xTg-AD mouse brains, it is necessary to also investigate Aβ accumulation and 
levels post-AAV9 gene therapy, however, our lab has had difficulty obtaining quality antibodies 
which could be used to evaluate Aβ levels on western blots.  
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